Lipid-Based Nanosystem As Intelligent Carriers for Versatile Drug Delivery Applications

Author(s): Harshita, Md. Abul Barkat, Sabya S. Das, Faheem H. Pottoo, Sarwar Beg, Ziyaur Rahman*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 11 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

The contemporary drug discovery research shows that most of the drug candidates are highly potent, but showing poor aqueous solubility leads a variety of challenges for formulation scientists to develop a suitable formulation to improve the systemic bioavailability of such drugs. Lipid-based nanocarriers act as a major and most projecting approach overcoming the limitations which affect several physiochemical properties of drug such as the solubility, partition coefficient and bioavailability or absorption. This also fulfills a variety of product requirements and helps to overcome several limitations as decided by symptoms of the disease, various routes of administration of drug, price concern, increasing strength of product, noxious or harmful effect of drug, and dose efficacy. The lipidic nanosystem formulates aqueous drug in lipid base and is also a commercially feasible approach for the formulation of different dosage forms meant for topical or transdermal, oral, ocular, pulmonary, and parenteral delivery. This review provides a brief on lipid-based drug delivery nanocarrier and the mechanisms by which lipids and lipidic excipients improve the oral absorption of drugs with poor aqueous solubility and also provide a viewpoint on the promising applications of lipidic nanoparticulate systems.

Keywords: Drug discovery, lipid-based nanocarriers, physiochemical properties, bioavailability, poor aqueous solubility, aqueous drug.

[1]
Anthony A. Attama, Mumuni A. Momoh and Philip F. Builders (2012). lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development, recent advances in novel drug carrier systems. Available at: https://www.intechopen.com/books/recent-advances-in-novel-drug-carrier-systems/lipid-nanoparticulate-drug-delivery-systems-a-revolution-in-dosage-form-design-and-development
[http://dx.doi.org/10.5772/50486.]
[2]
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5): 631-51.
[http://dx.doi.org/10.1016/S0169-409X(02)00044-3] [PMID: 12204596]
[3]
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55(3): 329-47.
[http://dx.doi.org/10.1016/S0169-409X(02)00228-4] [PMID: 12628320]
[4]
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(1)(Suppl. 1): S131-55.
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] [PMID: 12460720]
[5]
Gershkovich P, Wasan KM, Barta CA. A review of the application of lipid-based systems in systemic, dermal/ transdermal, and ocular drug delivery. Crit Rev Ther Drug Carrier Syst 2008; 25(6): 545-84.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v25.i6.20] [PMID: 19166393]
[6]
Pavelić Z, Skalko-Basnet N, Filipović-Grcić J, Martinac A, Jalsenjak I. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 2005; 106(1-2): 34-43.
[http://dx.doi.org/10.1016/j.jconrel.2005.03.032] [PMID: 15979189]
[7]
Benameur H. Liquid and semi-solid formulations for enhancing oral absorption. Bulletin Tech Gattefosse 2006; 99(1): 63-75.
[8]
Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008; 60(6): 625-37.
[http://dx.doi.org/10.1016/j.addr.2007.10.010] [PMID: 18068260]
[9]
Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6(3): 231-48.
[http://dx.doi.org/10.1038/nrd2197] [PMID: 17330072]
[10]
Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008; 129(1): 1-10.
[http://dx.doi.org/10.1016/j.jconrel.2008.03.021] [PMID: 18499294]
[11]
Jain KK. Drug delivery systems - an overviewdrug delivery systems totowa. Humana Press 2008; pp. 1-50.
[http://dx.doi.org/10.1007/978-1-59745-210-6_1]
[12]
Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29(3-4): 278-87.
[http://dx.doi.org/10.1016/j.ejps.2006.04.016] [PMID: 16815001]
[13]
Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci 2000; 11(Suppl. 2): S93-8.
[http://dx.doi.org/10.1016/S0928-0987(00)00167-6] [PMID: 11033431]
[14]
Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992; 9(1): 87-93.
[http://dx.doi.org/10.1023/A:1018987928936] [PMID: 1589415]
[15]
Feeney OM, Crum MF, McEvoy CL, et al. 50years of oral lipid-based formulations: Provenance, progress and future perspectives. Adv Drug Deliv Rev 2016; 101: 167-94.
[http://dx.doi.org/10.1016/j.addr.2016.04.007] [PMID: 27089810]
[16]
Westesen K, Siekmann B. Biodegradable colloidal drug carrier systems based on solid lipids. Drugs PharmaceutSci 1996; 73: 213-58.
[17]
Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci 2009; 147-148: 333-42.
[http://dx.doi.org/10.1016/j.cis.2008.07.007] [PMID: 18804754]
[18]
Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008; 5(1): 25-44.
[http://dx.doi.org/10.1517/17425247.5.1.25] [PMID: 18095927]
[19]
Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011; 85(2): 262-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.038] [PMID: 21435845]
[20]
Talluri SV, Kuppusamy G, Karri VV, Tummala S, Madhunapantula SV. Lipid-based nanocarriers for breast cancer treatment - comprehensive review. Drug Deliv 2016; 23(4): 1291-305.
[http://dx.doi.org/10.3109/10717544.2015.1092183] [PMID: 26430913]
[21]
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4(2): 145-60.
[http://dx.doi.org/10.1038/nrd1632] [PMID: 15688077]
[22]
Gulati M, Grover M, Singh S, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 1998; 165: 129-68.
[http://dx.doi.org/10.1016/S0378-5173(98)00006-4]
[23]
Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008; 99(3): 392-7.
[http://dx.doi.org/10.1038/sj.bjc.6604483] [PMID: 18648371]
[24]
Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004; 31(6)(Suppl. 13): 5-15.
[http://dx.doi.org/10.1053/j.seminoncol.2004.08.001] [PMID: 15717735]
[25]
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50(1): 161-77.
[http://dx.doi.org/10.1016/S0939-6411(00)00087-4] [PMID: 10840199]
[26]
Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56(9): 1257-72.
[http://dx.doi.org/10.1016/j.addr.2003.12.002] [PMID: 15109768]
[27]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[28]
Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59(6): 491-504.
[http://dx.doi.org/10.1016/j.addr.2007.04.008] [PMID: 17532091]
[29]
Kumar S, Randhawa JK. High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater Sci Eng C 2013; 33(4): 1842-52.
[http://dx.doi.org/10.1016/j.msec.2013.01.037] [PMID: 23498204]
[30]
Harshita , Barkat MA, Rizwanullah M, et al. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS Pharm Sci Tech 2019; 20(2): 87.
[http://dx.doi.org/10.1208/s12249-019-1304-4] [PMID: 30675689]
[31]
Müller RH, Souto EB, Radtke M. PCT application PCT/EP00/04111 2000.
[32]
Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN)- an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41: 62-9.
[33]
Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002; 10(5): 387-96.
[http://dx.doi.org/10.1080/1061186021000001832] [PMID: 12442809]
[34]
Cevc G, Gebauer D, Stieber J, Schätzlein A, Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1998; 1368(2): 201-15.
[http://dx.doi.org/10.1016/S0005-2736(97)00177-6] [PMID: 9459598]
[35]
Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 2002; 1564(1): 21-30.
[http://dx.doi.org/10.1016/S0005-2736(02)00401-7] [PMID: 12100992]
[36]
Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70.
[http://dx.doi.org/10.1016/S0378-5173(98)00169-0]
[37]
Conacher M, Alexander J, Brewer JM. Niosomes as immunological adjuvantssynthetic surfactant vesicles. Singapore: International Publishers Distributors 2000; pp. 185-205.
[38]
Onuigbo EB. Evaluation of Cationic Liposome- or Noisome-Based Antigen Delivery Systems for Newcastle Disease Vaccine. Ph.D. thesis. University of Nigeria; Nsukka. 2011.
[39]
Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol 2007; 73(3): 157-61.
[http://dx.doi.org/10.4103/0378-6323.32709] [PMID: 17558046]
[40]
Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today 2010; 15(23-24): 1032-40.
[http://dx.doi.org/10.1016/j.drudis.2010.09.006] [PMID: 20934534]
[41]
Charles L, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol 2011; 2: 626-39.
[http://dx.doi.org/10.4236/jbnb.2011.225075]
[42]
Kotta S, Khan AW, Pramod K, Ansari SH, Sharma RK, Ali J. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 2012; 9(5): 585-98.
[http://dx.doi.org/10.1517/17425247.2012.668523] [PMID: 22512597]
[43]
Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release 2000; 69(1): 209-18.
[http://dx.doi.org/10.1016/S0168-3659(00)00309-6] [PMID: 11018558]
[44]
YingjieZhai, Guangxi Zhai. Advances in lipid-based colloid systems as drug carrier for topic delivery. J Control Release 2014; 193: 90-9.
[45]
Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci 2005; 26(2): 219-30.
[http://dx.doi.org/10.1016/j.ejps.2005.06.005] [PMID: 16087324]
[46]
Chauhan B, Shimpi S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS PharmSciTech 2005; 6(3): E405-12.
[http://dx.doi.org/10.1208/pt060350] [PMID: 16353998]
[47]
Shrestha Hina, Bala Rajni, Arora Sandeep. Lipid-based drug delivery systems. J Pharm 2014: 10.
[http://dx.doi.org/10.1155/2014/801820]
[48]
Venkatesan N, Yoshimitsu J, Ohashi Y, et al. Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs. Int J Pharm 2006; 310(1-2): 46-52.
[http://dx.doi.org/10.1016/j.ijpharm.2005.11.014] [PMID: 16439074]
[49]
Venkatesan N, Yoshimitsu J, Ito Y, Shibata N, Takada K. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 2005; 26(34): 7154-63.
[http://dx.doi.org/10.1016/j.biomaterials.2005.05.012] [PMID: 15967493]
[50]
Ito Y, Kusawake T, Ishida M, Tawa R, Shibata N, Takada K. Oral solid gentamicin preparation using emulsifier and adsorbent. J Control Release 2005; 105(1-2): 23-31.
[http://dx.doi.org/10.1016/j.jconrel.2005.03.017] [PMID: 15908031]
[51]
Chambin O, Jannin V. Interest of multifunctional lipid excipients: case of Gelucire 44/14. Drug Dev Ind Pharm 2005; 31(6): 527-34.
[http://dx.doi.org/10.1080/03639040500215750] [PMID: 16109625]
[52]
Evrard B, Amighi K, Beten D, Delattre L, Moës AJ. Influence of melting and rheological properties of fatty binders on the melt granulation process in a high-shear mixer. Drug Dev Ind Pharm 1999; 25(11): 1177-84.
[http://dx.doi.org/10.1081/DDC-100102285] [PMID: 10596355]
[53]
Royce A, Suryawanshi J, Shah J, Vishnupad K. Alter- native granulation technique: melt granulation. Drug Dev Ind Pharm 1996; 22: 917-24.
[http://dx.doi.org/10.3109/03639049609065921]
[54]
Seo A, Schaefer T. Melt agglomeration with polyethylene glycol beads at a low impeller speed in a high shear mixer. Eur J Pharm Biopharm 2001; 52(3): 315-25.
[http://dx.doi.org/10.1016/S0939-6411(01)00183-7] [PMID: 11677074]
[55]
Seo A, Holm P, Kristensen HG, Schaefer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int J Pharm 2003; 259(1-2): 161-71.
[http://dx.doi.org/10.1016/S0378-5173(03)00228-X] [PMID: 12787644]
[56]
Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm Res 2005; 22(10): 1727-34.
[http://dx.doi.org/10.1007/s11095-005-6694-1] [PMID: 16180131]
[57]
Thies C, Dos Santos R, Richard J, Vandevelde V, Rolland H, Benoit J-P. A supercritical fluid-based coating technology 1: process considerations, vo Physicochemical characterization of solid dispersions of carbamazepine formulated by super- critical carbon dioxide and conventional solvl. J Microencapsul 2003; 20(1): 87-96.
[58]
Ribeiro Dos Santos I, Thies C, Richard J, et al. A supercritical fluid-based coating technology. 2: solubility considerations. J Microencapsul 2003; 20(1): 97-109.
[http://dx.doi.org/10.1080/02652040210162649] [PMID: 12519705]
[59]
Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci 2002; 91(9): 1948-57.
[http://dx.doi.org/10.1002/jps.10186] [PMID: 12210042]
[60]
Sethia S, Squillante E. In vitro-in vivo evaluation of supercritical processed solid dispersions: permeability and viability assessment in Caco-2 cells. J Pharm Sci 2004; 93(12): 2985-93.
[http://dx.doi.org/10.1002/jps.20199] [PMID: 15468328]
[61]
Naylor LJ, Bakatselou V, Rodriguez-Hornedo N, Weiner ND, Dressman JB. Dissolution of steroids in bile salt solutions is modified by the presence of lecithin. Eur J Pharm Biopharm 1995; 41(6): 346-53.
[62]
Shukla D, Chakraborty S, Singh S, Mishra B. Lipid-based oral multiparticulate formulations - advantages, technological advances and industrial applications. Expert Opin Drug Deliv 2011; 8(2): 207-24.
[http://dx.doi.org/10.1517/17425247.2011.547469] [PMID: 21210754]
[63]
Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res 2004; 21(8): 1405-12.
[http://dx.doi.org/10.1023/B:PHAM.0000036914.22132.cc] [PMID: 15359575]
[64]
Erlanson-Albertsson C. Pancreatic colipase. Structural and physiological aspects. Biochim Biophys Acta 1992; 1125(1): 1-7.
[http://dx.doi.org/10.1016/0005-2760(92)90147-N] [PMID: 1567900]
[65]
Borgstrom B. On the mechanism of pancreatic lipolysis of glycerides. Biochim Biophys Acta 1954; 13(4): 491-504.
[http://dx.doi.org/10.1016/0006-3002(54)90365-0] [PMID: 13159986]
[66]
van den Bosch H, Postema NM, de Haas GH, van Deenen LL. On the positional specificity of phospholipase A from pancreas. Biochim Biophys Acta 1965; 98(3): 657-9.
[http://dx.doi.org/10.1016/0005-2760(65)90168-2] [PMID: 5837465]
[67]
Borgstrom B, Dahlqvist A, Lundh G, Sjovall J. Studies of intestinal digestion and absorption in the human. J Clin Invest 1957; 36(10): 1521-36.
[http://dx.doi.org/10.1172/JCI103549] [PMID: 13475490]
[68]
Thomson ABR, Keelan M, Garg ML, Clandinin MT. Intestinal aspects of lipid absorption: in review. Can J Physiol Pharmacol 1989; 67(3): 179-91.
[http://dx.doi.org/10.1139/y89-031] [PMID: 2663123]
[69]
Moreau H, Bernadac A, Gargouri Y, Benkouka F, Laugier R, Verger R. Immunocytolocalization of human gastric lipase in chief cells of the fundic mucosa. Histochemistry 1989; 91(5): 419-23.
[http://dx.doi.org/10.1007/BF00493829] [PMID: 2656594]
[70]
Hamosh M, Scanlon JW, Ganot D, Likel M, Scanlon KB, Hamosh P. Fat digestion in the newborn. Characterization of lipase in gastric aspirates of premature and term infants. J Clin Invest 1981; 67(3): 838-46.
[http://dx.doi.org/10.1172/JCI110101] [PMID: 7204558]
[71]
Abrams CK, Hamosh M, Lee TC, et al. Gastric lipase: localization in the human stomach. Gastroenterology 1988; 95(6): 1460-4.
[http://dx.doi.org/10.1016/S0016-5085(88)80063-5] [PMID: 3181673]
[72]
Chapus C, Sémériva M, Bovier-Lapierre C, Desnuelle P. Mechanism of pancreatic lipase action. 1. Interfacial activation of pancreatic lipase. Biochemistry 1976; 15(23): 4980-7.
[http://dx.doi.org/10.1021/bi00668a006] [PMID: 990257]
[73]
Duane WC, Ginsberg RL, Bennion LJ. Effects of fasting on bile acid metabolism and biliary lipid composition in man. J Lipid Res 1976; 17(3): 211-9.
[PMID: 932555]
[74]
Cunningham KM, Daly J, Horowitz M, Read NW. Gastrointestinal adaptation to diets of differing fat composition in human volunteers. Gut 1991; 32(5): 483-6.
[http://dx.doi.org/10.1136/gut.32.5.483] [PMID: 2040469]
[75]
Cannon JB, Long MA. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery, part II. Water-insouluble drug formulation. 2nd ed. 2008.
[http://dx.doi.org/10.1201/9781420009552.ch11]
[76]
Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci 2007; 96(2): 235-48.
[http://dx.doi.org/10.1002/jps.20780] [PMID: 17051593]
[77]
Akhtar N, Ahad A, Khar RK, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 2011; 21(4): 561-76.
[http://dx.doi.org/10.1517/13543776.2011.561784] [PMID: 21413912]
[78]
Aungst BJ. Absorption enhancers: applications and advances. AAPS J 2012; 14(1): 10-8.
[http://dx.doi.org/10.1208/s12248-011-9307-4] [PMID: 22105442]
[79]
Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review. Adv Drug Deliv Rev 2013; 65(13-14): 1828-51.
[http://dx.doi.org/10.1016/j.addr.2013.09.002] [PMID: 24055628]
[80]
Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm 2014; 11(8): 2566-78.
[http://dx.doi.org/10.1021/mp500298q] [PMID: 24950236]
[81]
Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther 1998; 284(1): 362-9.
[PMID: 9435199]
[82]
Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res 1993; 10(6): 857-64.
[http://dx.doi.org/10.1023/A:1018909210879] [PMID: 8321854]
[83]
Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm 2006; 64(1): 82-91.
[http://dx.doi.org/10.1016/j.ejpb.2006.03.011] [PMID: 16750354]
[84]
Fischer SM, Brandl M, Fricker G. Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. Eur J Pharm Biopharm 2011; 79(2): 416-22.
[http://dx.doi.org/10.1016/j.ejpb.2011.04.010] [PMID: 21549839]
[85]
Fischer SM, Flaten GE, Hagesæther E, Fricker G, Brandl M. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. J Pharm Pharmacol 2011; 63(8): 1022-30.
[http://dx.doi.org/10.1111/j.2042-7158.2011.01301.x] [PMID: 21718285]
[86]
Miller JM, Beig A, Krieg BJ, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm 2011; 8(5): 1848-56.
[http://dx.doi.org/10.1021/mp200181v] [PMID: 21800883]
[87]
Katneni K, Charman SA, Porter CJ. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci 2007; 96(2): 280-93.
[http://dx.doi.org/10.1002/jps.20779] [PMID: 17051595]
[88]
Miller JM, Beig A, Carr RA, Webster GK, Dahan A. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol Pharm 2012; 9(3): 581-90.
[http://dx.doi.org/10.1021/mp200460u] [PMID: 22280478]
[89]
Ingels F, Beck B, Oth M, Augustijns P. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm 2004; 274(1-2): 221-32.
[http://dx.doi.org/10.1016/j.ijpharm.2004.01.014] [PMID: 15072798]
[90]
Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004; 278(1): 119-31.
[http://dx.doi.org/10.1016/j.ijpharm.2004.03.001] [PMID: 15158955]
[91]
Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. J Control Release 2007; 124(1-2): 1-5.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.021] [PMID: 17900739]
[92]
Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003; 92(6): 1250-61.
[http://dx.doi.org/10.1002/jps.10395] [PMID: 12761814]
[93]
Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002; 4(4)E40
[http://dx.doi.org/10.1208/ps040440] [PMID: 12646011]
[94]
Chiu Y-Y, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 2003; 20(5): 749-56.
[http://dx.doi.org/10.1023/A:1023481418576] [PMID: 12751630]
[95]
Christiansen A, Backensfeld T, Denner K, Weitschies W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur J Pharm Biopharm 2011; 78(1): 166-72.
[http://dx.doi.org/10.1016/j.ejpb.2010.12.033] [PMID: 21220010]
[96]
Patel JP, Brocks DR. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 2009; 5(11): 1385-98.
[http://dx.doi.org/10.1517/17425250903176439] [PMID: 19663632]
[97]
Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 2007; 59(15): 1482-503.
[http://dx.doi.org/10.1016/j.addr.2007.08.017] [PMID: 18198495]
[98]
Trevaskis NL, Porter CJ, Charman WN. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos 2006; 34(5): 729-33.
[http://dx.doi.org/10.1124/dmd.105.008102] [PMID: 16467133]
[99]
Gupta SK, Benet LZ. High-fat meals increase the clearance of cyclosporine. Pharm Res 1990; 7(1): 46-8.
[http://dx.doi.org/10.1023/A:1015831408425] [PMID: 2300535]
[100]
Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87(8): 936-42.
[http://dx.doi.org/10.1021/js9704846] [PMID: 9687337]
[101]
Charman WNA, Stella VJ. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int J Pharm 1986; 33: 165-72.
[http://dx.doi.org/10.1016/0378-5173(86)90050-5]
[102]
Trevaskis NL, Shanker RM, Charman WN, Porter CJ. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res 2010; 27(9): 1949-64.
[http://dx.doi.org/10.1007/s11095-010-0199-2] [PMID: 20635194]
[103]
Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev 1997; 25: 71-89.
[http://dx.doi.org/10.1016/S0169-409X(96)00492-9]
[104]
Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001; 50(1-2): 61-80.
[http://dx.doi.org/10.1016/S0169-409X(01)00151-X] [PMID: 11489334]
[105]
Khoo SM, Shackleford DM, Porter CJH, Edwards GA, Charman WN. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm Res 2003; 20(9): 1460-5.
[http://dx.doi.org/10.1023/A:1025718513246] [PMID: 14567642]
[106]
Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov 2015; 14(11): 781-803.
[http://dx.doi.org/10.1038/nrd4608] [PMID: 26471369]
[107]
Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 2008; 128(2): 269-80.
[http://dx.doi.org/10.1248/yakushi.128.269] [PMID: 18239375]
[108]
Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59(6): 478-90.
[http://dx.doi.org/10.1016/j.addr.2007.04.007] [PMID: 17543416]
[109]
Choi WJ, Kim JK, Choi SH, Park JS, Ahn WS, Kim CK. Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials 2004; 25(27): 5893-903.
[http://dx.doi.org/10.1016/j.biomaterials.2004.01.031] [PMID: 15172502]
[110]
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
[http://dx.doi.org/10.1016/S0169-409X(01)00105-3] [PMID: 11311991]


promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 11
Year: 2020
Published on: 23 April, 2020
Page: [1167 - 1180]
Pages: 14
DOI: 10.2174/1381612826666200206094529

Article Metrics

PDF: 26
HTML: 5